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Abstract 
 
Aim: To identify, appraise and synthesise the available evidence relating to the value and impact of 
cancer nursing on patient experience and outcomes. 
Background: There is a growing body of literature that recognises the importance and contribution 
of cancer nurses, however a comprehensive review examining how cancer nurses impact on care 
quality, patient outcomes and overall experience of cancer, as well as cost of services across the 
entire cancer spectrum is lacking.  
Design: A systematic review and meta-analysis using Cochrane methods. 
Methods: We will systematically search 10 electronic databases from 2000, with pre-determined 
search terms. No language restrictions will be applied. We will include all randomised and controlled 
before-and-after studies that compare cancer nursing interventions to a standard care or no 
intervention. Two reviewers will independently assess the eligibility of the studies and appraise 
methodological quality using the Cochrane Risk of Bias tool. Disagreements will be resolved by 
discussion, and may involve a third reviewer if necessary. Data from included studies will be 
extracted in accordance with the Template for intervention Description and Replication reporting 
guidelines. Missing data will be actively sought from all trialists. Data will be synthesised within 
evidence tables and narrative to answer three key questions. If sufficient data are available, we will 
perform meta-analyses.  
Discussion: This review will allow us to systematically assess the impact of cancer nursing on patient 
care and experience. This evidence will be used to determine implications for clinical practice and 
used to inform future program and policy decisions in Europe. 
 
Systematic review registration: The protocol is registered on PROSPERO as record no. 
CRD42016048760 
 
Summary statement: Why is this study or review needed?  Cancer nurses play a central role in caring for individuals diagnosed and living with, and 
beyond cancer. However in some countries across Europe, there is little recognition of the 
value of cancer nursing.  There is an emerging literature that recognises the importance of cancer nurses in caring for 
people with cancer; however a systematic review examining the impact and value of cancer 
nursing across the cancer spectrum is lacking.   This review is designed to systematically identify the roles and types of intervention 
activities currently undertaken by cancer nurses; and determine the effectiveness and cost-
effectiveness of interventions delivered by cancer nurses in improving the experience and 
outcomes of people with cancer.  
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INTRODUCTION 
Cancer is a leading cause of death worldwide. Recent studies estimate that 14.1 million new cases 
will be diagnosed each year; in more than half of these, patients will die as a direct result of the 
original cancer diagnosed (Torre et al. 2015). The impact of cancer on the individual, their family and 
wider society is incalculable. 
 
The cancer care pathway has been described as ͞Đoŵpleǆ, leŶgthǇ aŶd disjoiŶted, involving a wide 
ǀaƌietǇ of healthĐaƌe pƌofessioŶals iŶ a ƌaŶge of Đaƌe settiŶgs͟ (Henry 2015). As such, there is a need 
for an integrative role in cancer services, and this is typically fulfilled by the cancer nurse (Tiffany 
1987).   
 
Within the multi-disciplinary team, cancer nurses play an important, and often-varied role, in caring 
for individuals diagnosed with cancer in order to provide the best possible care. They deliver 
essential nursing care, patient, family, and community education and support; implement early 
detection programs; administer, monitor and in some settings evaluate treatments; identify and 
manage complications; provide supportive and palliative care; and lead and collaborate on clinical 
research (Beck 2016, CANO 2016, EONS 2012, ONS 2016).  
 
There is clear evidence linking cancer nurses care to improved patient outcomes. For example, 
specialist cancer nursing provision has been associated with improved management of chronic 
problems in cancer patients; positively impacting on patient knowledge and self-management; 
marked improvement in patient symptoms and a reduction in the rate of emergency admissions, 
length of hospital stays and fewer follow-up appointments (Corner et al. 2013, Sussman et al. 2011, 
Cockle-Hearne et al. 2013, Mick 2008, Rueda et al. 2011). Patient experience surveys in the UK have 
consistently identified the presence of a clinical nurse specialist as the factor most likely to be 
associated with a good experience of cancer care (Quality Health 2014).   
Previous reviews have synthesised the evidence for specific nurse-led interventions, for example, 
psychosocial and supportive care nursing interventions in breast cancer (Cruickshank et al. 2008, 
Eicher et al. 2006); nurse-led interventions involving telephone contact in women with 
gynaecological cancer (Cook et al. 2015); psychotherapeutic, psychosocial and educational 
interventions in patients with lung cancer (Rueda et al. 2011) and active surveillance and nurse-led 
care related to radiotherapy treatment and patients' experiences of radiotherapy treatment in men 
diagnosed with prostate cancer (Tarnhuvud et al. 2007, Madsen and Symes 2013). However, none 
haǀe foĐused oŶ the iŵpaĐt of ĐaŶĐer ŶursiŶg oŶ patieŶts͛ eǆperieŶĐes aŶd outĐoŵes across the 
spectrum of cancer.  
 
Background 
Facilitating the recognition of oncology nursing across Europe 
There is a general consensus that cancer nurses make a valuable and unique contribution to the 
quality and effectiveness of cancer treatment and care. However, there is little agreement about the 
role of the cancer nurse, and what training or education elements are important for the continued 
growth of the profession. As a result, there is significant variation in the provision and recognition of 
cancer nurses across Europe (Sermeus et al. 2011, Aiken et al. 2014). 
Although several professional bodies have made attempts to clarify the role, a lack of consensus 
regarding terminology continues to impede research and clinical practice (EONS 2012, CANO 2016, 
ONS 2016). One survey recently reported a wide variety of job titles across 17 countries in Europe 
(see Figure 1 – additional online only file), and identified 7 titles in the UK alone (Kav 2013).  
This lack of agreement means that it is ͞diffiĐult to gaiŶ aŶǇ ĐoŶsisteŶĐǇ oƌ ŶatioŶǁide agƌeeŵeŶt oŶ 
the qualifiĐatioŶs aŶd Ƌualities that aƌe ƌeƋuiƌed ďǇ speĐialist Ŷuƌses͟ (Henry 2015). 
Consequently, in 2015, the European Cancer Organisation (ECCO) Board decided that one of its top 
priorities would be to encourage the recognition of oncology nursing across Europe. In the same 
year – the European Oncology Nursing Society (EON“Ϳ, Europe͛s largest ĐaŶĐer ŶursiŶg orgaŶisatioŶ 
– set its strategiĐ aiŵ as: ͚To streŶgtheŶ EON“ politiĐal ǀoiĐe aŶd iŵpaĐt soĐietǇ aĐross Europe͛. This 
complementary and synergistic approach resulted in a new three-stage project that was launched on 
7 March 2016 – the Recognising European Cancer Nursing (RECaN) project (Trueland 2016). Stage 
one will include a systematic review of the impact of cancer nursing on patient experience and 
outcomes.  
 
Preliminary scoping work 
In order to develop an informed, consensual research protocol, designed to meet the aims of the 
EONS and ECCO joint project, key preliminary scoping work was first completed. This involved 
consultation and collaboration with the review authors, who comprised of selected experts in cancer 
nursing and research methods (see Table 1 for a summary of their expertise). 
 
Add Table 1 about here 
 
To inform the protocol development and decisions of the working group, an initial scoping review of 
the literature was completed.  
This scoping review involved systematic searching of 8 electronic databases:  Allied and Complementary Medicine Database (AMED);   Cochrane Central Register of Controlled Trials (CENTRAL);   Cochrane Database of Systematic Reviews (CDSR);   Database of Abstracts of Reviews of Effectiveness (DARE);   Health Technology Assessment (HTA);   Cumulative Index of Nursing and Allied Health Literature (CINAHL);  Medical Literature Analysis and Retrieval System Online (MEDLINE);   Excerpta Medica Database (EMBASE)  
 
We searched each database from inception onwards, combining the search terms cancer nursing 
with terms for cancer (see Appendix 1 for an example search string). This work will form the basis for 
an evidence map of the role and impact of cancer nursing and will be published in more detail 
elsewhere. 
 
A protocol was initially drafted by two members of the research team (PC, CT) with specialist input 
from MW, and then further refined by expert members of the working group. The identified 
definitions and key areas of the protocol were considered and discussed by members of the working 
group at a face-to-face meeting in June 2016.   
 
Discussion amongst expert members led to consensus over: 
(1) definitions of cancer nursing which should be used within the research protocol, and  
(2) key criterion underpinning the review (e.g. participant group; outcome measures and specific 
research questions to be addressed within the research). These are described in detail below. 
 
As a group of nurses with a vested interest in cancer nursing and its value, we recognise the 
potential for conflicts of interest.  All of our consensus decision meetings are therefore being 
recorded, to ensure transparency and enhance clarity around decisions. Data extraction is being 
independently conducted by two systematic reviewers, neither of whom are nurses (see Table 1). All 
co-authors have been involved in defining the scope of the review.    
 
Finally, it was agreed by all review authors that the active involvement of people affected by a 
cancer was critical to the success of the project; ensuring that the review would have real relevance, 
reach and engagement. We will consult patient representatives through ECCO Patient Advisory 
Committee (EPAC) at key stages in the review process and sought their initial views on the protocol. 
 
THE REVIEW 
 
Aim 
To identify, appraise and synthesise the available evidence relating to the value and impact of cancer 
nursing on patient experiences and outcomes. 
 
Research questions: 
Specifically, this review will seek to: 
1. Identify the roles and types of intervention activities that have been performed by cancer 
nurses; 
2. To determine the effectiveness and cost-effectiveness of interventions delivered by cancer 
nurses in improving the experience and outcomes of patients with cancer. 
3. Explore whether there is a relationship between cancer nurse education and training and patient 
experiences and outcomes.  
 
Design 
We plan to undertake a systematic review and meta-analysis using standard Cochrane methods 
(Higgins and Green 2011) and will report the data using well established methodology (Liberati et al. 
2009).    
 
Definition of a Cancer Nurse 
At present there is no universally accepted definition of a cancer nurse (Henry 2015). Nurses who 
work with people with cancer are referred to in various ways, for example, oncology nurses 
(Banerjee et al. 2016, Sherner 2016, Yu 2016); advanced practice nurses (Hendricks-Ferguson et al. 
2015, Gosselin et al. 2015, McCorkle et al. 2015, Spoelstra et al. 2016); specialist cancer nurses 
(Sykes et al. 2014, Taylor et al. 2014); clinical nurse specialists (Leary and Baxter 2014, Foster-
Mitchell 2016, Mishelmovich et al. 2016). 
 
Furthermore, ŵaŶǇ of the defiŶitioŶs are ďased arouŶd either ĐaŶĐer Ŷurses͛ role ;or the sĐope of 
the role); purpose; context and where care is being delivered; type or severity of cancer, and 
education/training or a combination of these factors. The ECCO PAC representatives highlighted the 
Ŷeed for ĐlaritǇ ǁheŶ defiŶiŶg a ĐaŶĐer Ŷurse, statiŶg that ͞there are many names for them, and the 
diffeƌeŶt aĐadeŵiĐ degƌee is ǀeƌǇ ĐoŶfusiŶg foƌ patieŶts͟. 
 
The expert group recognised the need to employ a broad definition that would allow the reviewers 
to be able to capture all nursing involvement, delivered at any stage of the patient journey (i.e. 
prevention and risk reduction, screening, diagnosis, treatment, survivorship, end-of-life care or 
anywhere along the continuum). 
The expert group considered a number of definitions from position papers and other relevant 
literature that were extracted during the scoping review. They agreed that the Canadian Association 
Nursing Organisation (CANO) definition for generalised, specialist and advanced oncology nurse – 
usiŶg the ǁord ͚ĐaŶĐer͛ iŶstead of ͚oŶĐologǇ͛ provided a flexible structure (Tiffany 1987, CANO 
2016). 
As such, the following definitions will be employed in the review: 
 Generalist nurse: defined as a nurse educated to degree level and may care for cancer patients 
in their daily caseload;   Specialist cancer nurse: educated to a degree level (or higher) with formal training in cancer 
who cares for cancer patients as a specialised population;   Advanced cancer nurse: educated at a post-graduate level and is considered an expert in at least 
one aspect of cancer nursing. 
We acknowledge that this definition may not be relevant or applicable to all international settings, 
and where nursing interventions are delivered to people with cancer by practitioners with 
alternative education/qualifications. Therefore we will judge whether these are equivalent to our 
definition of a cancer nurse, and will document the relevant information relating to education and 
qualifications. 
Criteria for considering studies for this review 
We plan to include any study that meets the following criteria: 
 
Types of studies 
We will include all relevant published:  randomised controlled trials (RCTs),  quasi-RCTs  cluster RCTs (cRCT)  controlled before and after studies (CBAs) 
 
For the purpose of this review, we have defined CBA studies as trials in which an outcome 
measurement(s) has been measured at baseline, and post-intervention for both groups. 
 
We will exclude case studies, surveys, reviews, editorials, policy reviews and statements, qualitative 
studies, and commentaries. The nature and focus of evidence excluded from the review will be 
captured in summary within the evidence map. Only studies published in peer-reviewed journals will 
be included. We will employ no language restrictions, but will limit the studies to those published 
from 1st January 2000 onwards. 
 
Types of participants 
Cancer nurses work across a spectrum of cancer and across population groups (e.g. children and 
young people diagnosed with cancer). As such, the expert working group (Table 1) felt that the 
review should reflect this, and include any study with participants diagnosed with cancer irrespective 
of their age. 
 
Types of interventions 
We will include any interventions delivered by a cancer nurse across the trajectory from prevention 
to end of life. The review will exclude any pharmacological or surgical only intervention, or any 
intervention delivered by healthcare professionals who are not professionally qualified nurses (e.g. 
support staff).   
 
Types of comparisons 
We will use direct pairwise comparisons and will plan to compare the following: 
1. Cancer nurse delivered interventions versus no intervention 
2. Cancer nurse delivered interventions versus standard or usual care (i.e. with no specialist cancer 
nurse intervention) 
3. One cancer nurse delivered intervention versus another cancer nurse delivered intervention 
4. One cancer nurse delivered intervention compared with an intervention delivered by other 
healthcare professionals. 
 
Types of outcome measures 
The primary outcomes of interest to this review are: 
1. Quality of life indicators as measured by a validated scale (e.g. EORTC QLQ-C30); well-being; 
symptoms (e.g. fatigue; nausea; vomiting); anxiety; depression; coping; social or financial 
functioning 
2. Cost effectiveness and other economic measures such as the cost of intervention; resource 
implications; cost-utility 
 
Secondary outcome measures will comprise: 
1. Mortality 
2. Recurrence/progression-free survival (PFS) / disease free survival 
3. Patient reported cancer specific outcomes measured by, for example, the Cancer 
Rehabilitation Evaluation System (CARES; CARES-SF), Cancer Survivor Unmet Needs Measure 
(CaSUN) 
4. Self-management / activation 
5. Patient safety 
6. Adverse events 
7. Carer burden 
8. Physiological indicators  
9. Impact on policy 
10. Participant satisfaction (measured using a validated scale) 
11. Service provision 
12. Other outcomes not pre-specified but considered to be important during the review 
 
We will consider outcomes at the end of the intervention (immediate), up to one-year post-
iŶterǀeŶtioŶ ;≤ ϭϮ ŵoŶthsͿ, aŶd ŵore thaŶ oŶe-year post-intervention (>12 months). 
 
ECCO PAC representatives were asked to comment on the relevance of the outcome measures listed 
above, and agreed that quality of life indicators were the most important measure.  They also 
emphasised the need for adherence to therapy and key symptoms such as sleep problems to be 
considered. 
 
Further, the ECCO PAC highlighted the importance of carer burden as a secondary outcome 
measure, arguing, ͞foƌ some cancers in particular such as brain tumours, carers play a huge role 
ďeĐause the patieŶt’s phǇsiĐal aŶd ĐogŶitiǀe aďilities aƌe ofteŶ seǀeƌelǇ Đoŵpƌoŵised͟. 
 
Ethical considerations 
There are no ethical issues. 
 
Validity and reliability of review 
We have developed this protocol in accordance with the PRISMA protocol checklist (PRISMA-P) 
(Moher et al. 2015). We will conduct the systematic review and meta-analysis according to the 
Cochrane Handbook for Systematic Reviews of Interventions (Higgins and Green 2011) and report 
the data following the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement (Liberati et al. 2009).   
 
Search methods for identification of studies 
We will systematically search the following electronic databases from 1st January 2000.  Medline  AMED  Epistemonikos  CINAHL  Embase  Cochrane Central Register of Controlled Trials  CDSR  DARE  HTA   Clinical trial registries to identify any on-going trials (e.g. WHO ICTRP) 
A comprehensive search strategy will be developed according to the following search architecture 
and adapted for each database as required. 
We will combine key terms using a series of free text terms and MESH terms for: Profession and/role 
(e.g. nurse; nurse practitioner; cancer nurse; oncology nurse) and Cancer (e.g. neoplasm; tumour 
etc). Boolean operators will be used in order to maximise the penetration of terms searched, and 
appropriate ͞ǁild Đards͟ ǁill ďe used to aĐĐouŶt for plurals, ǀariatioŶs iŶ dataďases aŶd spelliŶg. AŶ 
example search strategy is provided in Appendix 1. We will look for additional studies by checking 
the reference lists of all included articles. 
 
Data collection and analysis 
Selection of studies 
One review author (PC) will read the titles of the identified references and eliminate any obviously 
irrelevant studies (e.g. not cancer related condition). We will obtain the abstracts for the remaining 
studies and then, based on the inclusion criteria (study design, diagnosis of cancer); two review 
authors (PC, CT) will independently rank these as relevant, irrelevant or unsure. 
 
We will exclude all studies ranked as irrelevant by both review authors, and obtain the full text of all 
remaining studies. Two review authors will independently assess the full texts of studies ranked as 
relevant or unsure for inclusion, and any disagreements will be resolved through discussion. If there 
is disagreement between reviewers, they will reach consensus through consideration and discussion 
of the full paper, involving a third reviewer if necessary. 
 
Data extraction and management 
We will systematically extract information relating to:  Study characteristics (author, date of publication and country of the study)  Aims of the study  Study design and methodology (e.g. research design, randomisation, stratification)  Participant characteristics  Intervention details; these will be reported in accordance with the template for intervention 
description and replication (TIDieR) checklist (Hoffmann et al. 2014). The TIDieR checklist 
supports complete descriptions of complex interventions to facilitate transparency and 
replication in a research or clinical context. We will extract data relating to the intervention 
rationale, materials, procedures, provider (including their expertise, qualifications and any 
specific training), delivery mode, dose, tailoring, modification, adherence and related 
aspects of fidelity. ECCO PAC representatives underscored the importance of the context of 
the care provided as an important consideration.  Outcomes assessed. Details of each assessed outcome will be documented, including time 
points for data collection.  Effectiveness data. Quantitative data relating to the effect of the intervention will be 
documented.  Number of participants contributing to data will be documented. Results of any statistical 
comparisons or tests will be extracted. No data relating to qualitative outcomes will be 
extracted. 
One reviewer (CT) will systematically extract the data, using a data collection form that has been 
specifically designed for this study. A second reviewer from the research team will independently 
check the data entry. 
 Data from the included studies will be processed as described in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins 2011) and it will be managed using the RevMan 
Analyses statistical programme in Review Manager (The Nordic Cochrane Centre 2014). 
 
Measures of treatment effect 
When appropriate, the results of included studies will be combined for each outcome in a formal 
meta-analysis to produce an overall estimate of treatment effect. For dichotomous data, risk ratio 
(RR) and 95% confidence intervals will be derived using a fixed effects model and, for continuous 
data, weighted mean differences (WMD), weighted by the inverse of the variance. 
 
Dealing with missing data 
We will deal with missing data according to the recommendations in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins and Green 2011). Where data is not reported 
adequately, attempts will be made to acquire the necessary information from the authors. We plan 
to assess whether the results were reported on attrition bias, and if not, whether the number and 
reasons for withdrawal and dropout were sought. 
 
Assessment of heterogeneity 
Trials will only be combined if they are thought to be clinically similar. Heterogeneity between trials 
will be assessed by visual inspection of plots of the data, the Chi2 test for heterogeneity and the I2 
statistic (Higgins and Green 2011). We will define the thresholds for interpretation of the I2 statistic 
according to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins and Green 
2011). Where we observe important heterogeneity (based of the I2 value together with significant 
evidence of heterogeneity as per the Chi2 test P value), we will employ a random effects model 
(Higgins and Green 2011). 
 
Assessment of reporting biases 
We are planning to investigate the possibility of publication bias with a funnel plot in comparisons 
within which we can include 10 or more studies. We will also reduce the effect of reporting bias by 
including studies - not just publications – thereby minimising the introduction of duplicate 
publications of the same dataset.   
 
Data Synthesis  
Data from included studies will be synthesised within evidence tables and narrative. We will group 
evidence according to type of outcome assessed. Where more than one study has assessed the same 
outcome, we will tabulate all effectiveness data and details of relevant studies. We will pool data 
from studies that are judged to be clinically homogeneous and tabulate this data using Review 
Manager 5.3 software (The Nordic Cochrane Centre 2014). If sufficient data are available, we will 
perform meta-analyses. When studies are statistically heterogeneous, we will use a random-effects 
model; otherwise, we plan to use a fixed-effect model. When using the random-effects model, we 
will conduct a sensitivity analysis using the fixed-effect model to reveal differences in results. We will 
include a 95% confidence interval (CI) for all estimates. We will present results separately for RCTs 
and CBA studies. 
 
We plan to carry out three separate syntheses – each answering one of the research questions.   
 
Assessment of risk of bias in included studies 
Two review authors from the research team will independently assess the methodological quality of 
included studies using the relevant risk of bias assessment tool from the Cochrane Collaboration 
(Higgins and Green 2011). 
We will assess the methodological quality across the following domains:  randomisation (i.e. sequence generation and concealment of randomisation). We will not 
judge CBA studies for the quality if random allocation because this item is not applicable to 
non-randomised studies.  blinding (participants, carers, outcome assessors);  selection bias in analysis (based on assessment of withdrawals) and dropouts (incomplete 
data; use of an intention to treat analysis);  selective reporting;  other potential sources of bias (e.g. provision of clear inclusion/exclusion criteria; baseline 
similarity of randomised groups). 
 
Assessment of quality of evidence 
We will use the GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
approach (Guyatt et al. 2008) to make a judgment on our confidence in the evidence relating to each 
specific outcome, ranking confidence in the evidence as high, moderate, low or very low. 
These are defined as:  High quality, when further research is very unlikely to change our confidence in the estimate of 
effect;  Moderate quality, when further research is likely to have an important impact on our confidence 
in the estimate of effect and may change the estimate;  Low quality, when further research is very likely to have an important impact on our confidence 
in the estimate of effect and is likely to change the estimate; or  Very low quality, when we are very uncertain about the estimate. 
 
Judgement of GRADE quality will be agreed through discussion involving at least three reviewers, 
and involving additional reviewers where there is disagreement. Furthermore, we will highlight 
where there is high or moderate quality evidence of an intervention having (i) benefit, (ii) harm or 
(iii) no benefit or harm. 
 
Subgroup analysis 
Where feasible we will perform subgroup analyses based on: 
1. Type of cancer 
2. Age group as reported ďǇ trialists ;e.g. ͞paediatriĐ͟ / ͞ǇouŶg adult or ǇouŶg persoŶ͟ / 
͞adult͟ / ͞older adult͟Ϳ 
3. Stage of cancer (prevention, early diagnosis, treatment, survivorship period, end-stage 
cancer) 
4. Category of cancer nurse involved (generalist nurse / specialist nurse / cancer nurse 
specialist) 
 Sensitivity analysis 
We will conduct a sensitivity analysis when indicated to test the robustness of the meta-analysis by 
omitting studies judged as high risk of bias. 
 
DISCUSSION 
The value and impact of cancer nursing is widely acknowledged as beneficial for patients. However, 
the roles of cancer nurses are often poorly reported, and their unique contribution to the cancer 
care pathway is not always captured. Furthermore, there are wider concerns about making the most 
of the available workforce - including nursing - across Europe, as well the 'greying' of the 
nursing workforce, and the rising expectations of patients. As such, there is an urgent need for 
robust evidence of the effectiveness of cancer nurses and their impact on patient experiences and 
outcomes. 
This planned systematic review and meta-analysis will therefore bring together all of the available 
studies that have evaluated the effectiveness of cancer nurses on patient experiences and outcomes 
in cancer care. This synthesis will also examine whether specialist cancer nursing training and 
education has any impact on the quality of care. 
Limitations 
There are some limitations to our review.  Reports and case studies highlighting the importance of 
specialist nurses in supporting decision making, linking services, providing emotional support and 
information will not meet the criteria for the review, but still illustrate the impact nurses have on 
improving quality of life for people affected by cancer  (Macmillan Cancer Support n.d.) Papers 
published before 2000 will not be included, and the review will not synthesise evidence from studies 
using qualitatiǀe or surǀeǇ desigŶs.  Hoǁeǀer, ǁe are ĐoŶduĐtiŶg a ĐoŶĐurreŶt ͚eǀideŶĐe ŵappiŶg͛ 
exercise, which will consider all types of study design since 2000 and will enable us to provide an 
overview of how the cancer nursing landscape has changed over the last fifteen years.   
 
CONCLUSION 
This review will be the first to synthesise evidence for cancer nursing across the whole cancer care 
ĐoŶtiŶuuŵ.  CoŵŵissioŶed ďǇ keǇ EuropeaŶ ĐaŶĐer orgaŶisatioŶs, the reǀieǁ͛s fiŶdiŶgs ǁill ďe used 
to help influence policy and practice across the continent, highlighting the potential for specialist 
cancer nurses to impact on patient outcomes and experiences and providing the evidence to 
underpin developments in education and clinical practice so that the value of cancer nursing is 
recognised and optimised in all European countries. There is potential to enhance the role of 
specialist cancer nurses and this review will help in this process by clarifying the contribution that 
nursing has made. 
 
 
List of abbreviations 
CBA: Controlled before-after studies 
cRCT: Cluster randomised controlled trial 
GRADE: Grading of Recommendations, Assessment, Development and Evaluation 
qRCT: quasi-randomised controlled trial 
RCT: Randomised controlled trials 
TIDieR: Template for intervention description and replication 
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